Novartis has entered an agreement with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of hydroxychloroquine to treat hospitalised patients with Covid-19.
Hydroxychloroquine, which is commonly used to treat malaria and some autoimmune diseases, showed anti-SARS-CoV-2 activity in laboratory tests.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sponsored by Novartis, the new Phase III trial will assess hydroxychloroquine as a potential Covid-19 therapy in around 440 participants.
